As Keryx Moves Closer To Phase III Results, Partnership Options Heat Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data readout on perifosine in colorectal cancer patients will spark a partnership or acquisition, CEO Ron Bentsur predicts during a Q2 call.